Lumenis VersaPulse PowerSuite

...ls cover the range from 2ul to 5000ul. Fills and ...revents inadvertent volume change. Novel hand gri...e is autoclavable at 121C(250F). To prevent corro...le for one-handed operation. Auto or Normal trigg...

Pipetman Ultra is a fully adjustable, air-displacement pipette with a patented multifunctional electronic display. It is the latest member of the Pipetman family, sharing many of the same characteris

...ion, ergonomics, and value!, Comfortable feel and...andle , Finer control while pipetting with smooth,...able for easy decontamination and sterilization wi...ecision micrometer for reproducible, accurate volu...

Medicine Products:

Autoclavable Pipette P2 Pipetman Ultra U2 SoftGrip 0.2-2 L Adjustable Volume Pipette Autoclavable Pipette P5000

(Date:8/7/2008)...r continues support of activities fostering total ...erves, PASADENA, Calif., Aug. 7 /PRNewswire/ -- K...based nonprofit organization, today announced that...r of the 2008 Pasadena,Marathon. The inaugural rac...e flagship event for Pasadena Forward., Kaiser Pe...

(Date:8/7/2008)...recognize best practices in consumer decision-maki...th care management spectrum, WASHINGTON, Aug. 7 /...,than thirty of the nation,s foremost thought lead...or its 2009 Best Practices in Health Care,Consumer...ices awards,recognize innovative and proven progra...

(Date:8/7/2008)...Aug. 7 /PRNewswire-USNewswire/ -- The U.S. Governm...elopment (USAID), is providing,an initial $50,000 ...rgency,relief supplies to the flood-affected popul...s led to flooding in central and,southeastern Togo...capital,of Lome. The UN Development Program estima...

(Date:8/7/2008)...rves Beneficiary Access to High Quality Nursing Ho... Staffing Efforts, JOPLIN, Mo., Aug. 7 /PRNewswir... protecting the nation,s critical frontline-caregi...r Care (CPSC) today thanked,Senator Pat Roberts fo...in,Congress to stop the Bush Administration from m...

Breaking Medicine News(10 mins):Health News:Kaiser Permanente Becomes Presenting Sponsor for Pasadena Marathon 2 Health News:URAC Reveals Distinguished Judges' Panel for 2009 Best Practices in Health Care Consumer Empowerment and Protection Awards 2 Health News:URAC Reveals Distinguished Judges' Panel for 2009 Best Practices in Health Care Consumer Empowerment and Protection Awards 3 Health News:Senator Pat Roberts Praised for Leading Successful Effort to Derail $6.2 Million Kansas Medicare Cuts 2

[0] Kaiser Permanente Becomes Presenting Sponsor for Pasadena Marathon [0] URAC Reveals Distinguished Judges' Panel for 2009 Best Practices in Health Care Consumer Empowerment and Protection Awards [0] USAID Provides Assistance to Togo Flood Victims [0] Senator Pat Roberts Praised for Leading Successful Effort to Derail $6.2 Million Kansas Medicare Cuts

...ntries should put their heads together, and share ...cting people across nationalities from a dreaded f...e international effort in the development of a vac...ng of important information regarding influenza vi...

...ording to the scientists from the University of Ne...lammatory bowel disease can eliminate the damage c...e usual belief that fibrosis; the scarring linked ...the recent study on animals revealed that the dama...

...tland: Many thousands of stroke victims suffer vis...ists in Aberdeen have conceived //a device that ho... impairment of vision. According to the Aberdeen ...been devised that is capable of arousing the blind...

... Cape Times has reported that illegal medicines ar...red products being sold on the streets//. The repo...culosis and HIV/Aids.A source in the country's hea...t of control. "The belief is that they can't close...

Other Medicine News:

When Bird- Flu takes Flight Arthritis Drug to Reverse Cirrhosis Eye-opener for Stroke Victims Suffering Partial Vision Loss Illegal Medicines Swamp SA Markets

(Date:8/7/2008)...wswire/ -- ProteoTech Inc. (ProteoTech),today anno...onal New Drug,(IND) requirements and has been clea...cal trial on Exebryl-1(R), a novel small molecule ...tion for the treatment of Alzheimer,s,disease. Pro...29, 2008., At the 2008 International Conference o...

(Date:8/7/2008)...ve Decision to Expand its Proprietary ...rland, Aug. 7 /- ESBATech AG, a leadi...day announced that the,company has raised an addit...ries B venture round to expand its development pip...ticipated in this round including SV Life,Sciences...

(Date:8/6/2008)...ew Patent Granted, CAMBRIDGE, Mass. and CARLSBAD,...Corp. (Nasdaq: GENZ ) and Isis Pharmaceuticals, I...e begun a phase 3 study of mipomersen in,patients ...eFH), a genetic,disorder that causes exceptionally...f four new trials the companies plan to initiate b...

(Date:8/6/2008)...ire/ -- In the most recent issue of,Optometry & Vi...erman,scientist and researcher, Dr. Burkhart Fisch...ion problems have a hard time learning basic,mathe...therapy is given,math skills improve., Dr. Fisch...vision news,programs which reported on his researc...

Breaking Medicine Technology:ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease 2 ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing 2 ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing 3 Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 2 Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 3 Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 4 Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 5 Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 6 Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 7 Vision Problems Affect How Children Learn Math Skills 2 Cato Research Names John Cline as President 3887 1 Cato Research Names John Cline as President 3887 2 More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms 14105 1 More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms 14105 2 More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms 14105 3 Amilpar Revenues Increase by 32 25 and EBITDA Doubles in 2007 14102 1 Amilpar Revenues Increase by 32 25 and EBITDA Doubles in 2007 14102 2 Remarks Prepared for Delivery By Attorney General Michael B Mukasey At the Ministerial Press Conference 2474 1 Remarks Prepared for Delivery By Attorney General Michael B Mukasey At the Ministerial Press Conference 2474 2

[0] ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease [0] ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing [0] Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen [0] Vision Problems Affect How Children Learn Math Skills

...29, 2007 /PRNewswire/ --,Pieris AG, a bio-pharmace...prising of Anticalins(R), a novel proprietary clas...s demonstrated potent,anti-tumor activity of PRS-0...ific Anticalin(R) with extended serum half life, w...upporting the,development of a superior biotherape...

...Personal and Social,Performance, COLORADO SPRI...r-term treatment with INVEGA(TM) (paliperidone),...dication for,schizophrenia, helped many patients... their improvements in personal and social,funct...en label, international,clinical trial sponsored...

Other Medicine Technology:Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific,Anticalin in Preclinical Studies 2 Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific,Anticalin in Preclinical Studies 3 Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 2 Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 3 Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 4 Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 5 Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 6

Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific,Anticalin in Preclinical Studies Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control

Products	Lumenis VersaPulse PowerSuite
Company	Lumenis, Inc.
Item	Lumenis VersaPulse PowerSuite
Features	Immediate removal of tissue and symptoms. Virtually bloodless and minimally invasive technique. Typically one minute per gram is the average time Short catheterization time. Fewer complications. Shorter convalescence. Cost-effective solutions - hospitals gain unmatched economic benefits by utilizing the multipurpose holmium laser for stones, strictures, tumors AND BPH treatment.
Description	HoLAP is a safe, effective and relatively bloodless procedure for immediate resolution of BPH symptoms. It is easy to learn and can be performed in less than an hour in an outpatient setting with few if any patient complications. Surgeons can quickly master the procedure, minimize OR time and use a familiar technology with which they are comfortable. Patients experience few complications including no blood loss, no transfusions, no catheters after release and a quick return to normal activity. Facilities enjoy the economic benefits of utilizing a multipurpose system for many applications.
Info	Lumenis, Inc. Customer Service: 877-lumenis Web site: http://www.lumenis.com